Quantcast

Latest Friedreich's ataxia Stories

2010-11-04 17:52:30

Embargoed by the journal Cell Stem Cell until November 4, noon, Eastern time – Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

2010-08-05 06:00:00

WALTHAM, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the first quarter of fiscal year 2011, ended June 30, 2010.

2010-08-02 07:49:00

WALTHAM, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases.

2010-06-09 06:00:00

WALTHAM, Mass., June 9 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010.

2010-05-24 09:04:00

WALTHAM, Mass., May 24 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich's ataxia.

2010-05-13 06:00:00

WALTHAM, Mass., May 13 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor.

2010-04-16 06:00:00

WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010.

2010-03-18 09:45:00

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease. The Barteks are co-founders of the Friedreich's Ataxia Research Alliance, an organization dedicated to the pursuit of scientific research leading to treatments and a cure for the disease.

2010-02-04 07:00:00

WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the third quarter of fiscal year 2010, ended December 31, 2009.


Word of the Day
obdormition
  • Sleep; the state or condition of being asleep.
  • The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.
The word 'obdormition' comes from a Latin word meaning "to fall asleep".
Related